Abstract
Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
CNS & Neurological Disorders - Drug Targets
Title:Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior
Volume: 12 Issue: 7
Author(s): Maurizio Pompili, Gianluca Serafini, Mario Palermo, Maria Elena Seretti, Henry Stefani, Gloria Angeletti, David Lester, Mario Amore and Paolo Girardi
Affiliation:
Keywords: Suicidal behavior, stress, prolactin, HPA axis.
Abstract: Hypothalamic-Pituitary-Adrenal (HPA) axis hyperactivity measured with the dexamethasone suppression test and the dexamethesone/CRH test may have some predictive power for suicidal behavior in patients with mood disorders. Increased prolactin (PRL) levels may be related both to physiological and pathological conditions. HPA-axis abnormalities and increased levels of PRL may coexist, and common neuroendocrine changes may activate both HPA axis and PRL release. HPA-axis hyperactivity is presumably present in a large subpopulation of depressed subjects. Suicidal behavior is considered to be a form of inward-directed aggression, and aggressive behavior has been connected to high androgen levels. However, lower plasma total testosterone levels have also been reported in subjects with depression and higher suicidality. Lipid/immune dysregulations, the increased ratio of blood fatty acids, and increased PRL levels may each be associated with the increased production of pro-inflammatory cytokines, which have been reported in patients with major depression and patients engaging in suicidal behavior. Although no studies have been done to determine whether ante-mortem physical stress may be detected by raised post-mortem PRL, this would be of great interest for physicians.
Export Options
About this article
Cite this article as:
Pompili Maurizio, Serafini Gianluca, Palermo Mario, Seretti Elena Maria, Stefani Henry, Angeletti Gloria, Lester David, Amore Mario and Girardi Paolo, Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior, CNS & Neurological Disorders - Drug Targets 2013; 12(7) . https://dx.doi.org/10.2174/18715273113129990098
DOI https://dx.doi.org/10.2174/18715273113129990098 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pharmaceutical and Pharmacodynamic Evaluation of Naproxen Incorporated Aloe vera Transgel
Drug Delivery Letters Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Flavonoids, Vascular Function and Cardiovascular Protection
Current Pharmaceutical Design Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Programmed Cell Death after Intracerebral Hemorrhage
Current Neuropharmacology Damnacanthal-Induced Anti-Inflammation is Associated with Inhibition of NF-κB Activity
Inflammation & Allergy - Drug Targets (Discontinued) Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Diagnosis and Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Pharmacological Inhibitors of Cysteinyl Leukotrienes Biosynthesis: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Phospholipase D Inhibition: Beneficial and Harmful Consequences for a Double-Dealer Enzyme
Current Enzyme Inhibition Direct and Indirect Antimicrobial Activities of Neuropeptides and their Therapeutic Potential
Current Protein & Peptide Science Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Thymidine Phosphorylase and Fluoropyrimidines Efficacy: A Jekyl and Hyde Story
Current Medicinal Chemistry - Anti-Cancer Agents Long-term Potentiation at Spinal C-fiber Synapses: A Target for Pathological Pain
Current Pharmaceutical Design Matrix Metalloproteinases in Acute Coronary Syndromes: Current Perspectives
Current Topics in Medicinal Chemistry Tyrosinase Expression as a Molecular Marker for Investigating the Presence of Circulating Tumor Cells in Melanoma Patients
Current Cancer Drug Targets Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Current Update on Association Between Alzheimer’s Disease and Type 2 Diabetes: Volume I)
CNS & Neurological Disorders - Drug Targets